Tousignant J D, Gates A L, Ingram L A, Johnson C L, Nietupski J B, Cheng S H, Eastman S J, Scheule R K
Genzyme Corporation, Framingham, MA 01701, USA.
Hum Gene Ther. 2000 Dec 10;11(18):2493-513. doi: 10.1089/10430340050207984.
A major limitation associated with systemic administration of cationic lipid:plasmid DNA (pDNA) complexes is the vector toxicity at the doses necessary to produce therapeutically relevant levels of transgene expression. Systematic evaluation of these toxicities has revealed that mice injected intravenously with cationic lipid:pDNA complexes develop significant, dose-dependent hematologic and serologic changes typified by profound leukopenia, thrombocytopenia, and elevated levels of serum transaminases indicative of hepatocellular necrosis. Vector administration also induced a potent inflammatory response characterized by complement activation and the induction of the cytokines IFN-gamma, TNF-alpha, IL-6, and IL-12. These toxicities were found to be transient, resolving with different kinetics to pretreatment levels by 14 days posttreatment. The toxic syndrome observed was independent of the cationic lipid:pDNA ratio, the cationic lipid species, and the level of transgene expression attained. Mechanistic studies determined that neither the complement cascade nor TNF-alpha were key mediators in the development of these characteristic toxicities. Administration of equivalent doses of the individual vector components revealed that cationic liposomes or pDNA alone did not generate the toxic responses observed with cationic lipid:pDNA complexes. Only moderate leukopenia was associated with administration of cationic liposomes or pDNA alone, while only mild thrombocytopenia was noted in pDNA-treated animals. These results establish a panel of objective parameters that can be used to quantify the acute toxicities resulting from systemic administration of cationic lipid:pDNA complexes, which in turn provides a means to compare the therapeutic indices of these vectors.
质粒DNA(pDNA)复合物全身给药相关的一个主要限制是,在产生治疗相关水平转基因表达所需的剂量下,载体具有毒性。对这些毒性的系统评估表明,静脉注射阳离子脂质体:pDNA复合物的小鼠会出现显著的、剂量依赖性的血液学和血清学变化,其特征为严重的白细胞减少、血小板减少以及血清转氨酶水平升高,这表明肝细胞坏死。载体给药还引发了一种强烈的炎症反应,其特征为补体激活以及细胞因子IFN-γ、TNF-α、IL-6和IL-12的诱导。发现这些毒性是短暂的,在治疗后14天内以不同的动力学恢复到预处理水平。观察到的毒性综合征与阳离子脂质体:pDNA比例、阳离子脂质种类以及所达到的转基因表达水平无关。机制研究确定,补体级联反应和TNF-α都不是这些特征性毒性发展的关键介质。给予等量的单个载体成分表明,单独的阳离子脂质体或pDNA不会产生与阳离子脂质体:pDNA复合物观察到的毒性反应。单独给予阳离子脂质体或pDNA仅伴有中度白细胞减少,而在pDNA处理的动物中仅观察到轻度血小板减少。这些结果建立了一组客观参数,可用于量化阳离子脂质体:pDNA复合物全身给药导致的急性毒性,这反过来又提供了一种比较这些载体治疗指数的方法。